Otoacoustic Emission Screen Results in Critically Ill Neonates Who Received Gentamicin in the First Week of Life

Cooper, Aaron C; Commers, Amy R.; Finkelstein, Marsha; Lipnik, Polina G.; Tollefson, Lisa M.; Wilcox, Roger; Hoff, David

doi:10.1592/phco.31.7.649

Cited by 19 publications

(12 citation statements)

References 34 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They found a failure rate of 1st TEOAEs among 84 high risk neonates for hearing loss (including treatment by aminoglycosides) of 21.4% vs 9.8% in 448 healthy, failure rate of 2nd TEOAEs was 8.64% vs 1.37% in high risk vs healthy neonates respectively. Cooper et al [20] found 9.0% (40/ 443 neonates) failure rate of TEOAEs in non-VLBW neonates. VellaBrincat et al [21] showed 7% (85/1,233) failure rate in no gentamicin and no vancomycin group while gentamicin but no vancomycin group showed failure rate of 4% (42/949).…”

Section: Discussionmentioning

confidence: 98%

Gentamicin extended interval regimen and ototoxicity in neonates

El-Barbary

Ismail

Ibrahim

2015

International Journal of Pediatric Otorhinolaryngology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 98%

Gentamicin extended interval regimen and ototoxicity in neonates

El-Barbary

Ismail

Ibrahim

2015

International Journal of Pediatric Otorhinolaryngology

View full text Add to dashboard Cite

“…Even though ureterostomy induces a need for further surgery, it avoids part of the morbidity associated with pyelonephritis (antibiotics side effects, intravenous injection, and hospitalization) and selection of resistant bacteria due to repeated antibiotic pressure [29][30][31][32] .…”

Section: Morbiditymentioning

confidence: 99%

Critical Analysis of a Series of Early Inguinal Ureterostomies: Are They Useful and How Well Are They Tolerated?

Bouty

Lefèvre²,

Harper³

et al. 2016

Urol Int

View full text Add to dashboard Cite

Introduction: The study aimed to evaluate the advantages of temporary inguinal ureterostomy in the management of neonates with uropathies and early or recurrent pyelonephritis. Patients and Methods: We performed a retrospective analysis of all patients who underwent ureterostomies between 1989 and 2012, with specific regards to indications and outcomes. We also performed a survey of parents to evaluate their acceptance of diversion. Results: We included 18 patients (12 primary high-grade vesicoureteral reflux [VUR] and 6 primary obstructive megaureters [MUs]). Indications were recurrent febrile urinary tract infections (UTIs) despite antibiotic prophylaxis, doubtful function of the overlying kidney for the oldest cases, when renal function was only assessed by intravenous urography, or both. Cutaneous diversion was performed between the ages of 2 weeks to 5 months (median: 1.8 months). Renal function was assessed prior to undiversion to choose between reimplantation and nephrectomy. The incidence of febrile UTIs significantly decreased during the period of diversion. Urinary diversion was judged socially acceptable by parents. Ureterostomy did not modify the overlying kidney function. Conclusion: Temporary inguinal ureterostomy does not enable better evaluation of renal function by suppressing the pressure of an obstacle or refluxing urines. Its remaining indication seems to be the prevention of recurrent UTIs in neonates and infants with VUR or MU, pending reimplantation.

show abstract

“…Cooper et al 7 examined hearing loss in 528 infants receiving a high doses of gentamicin. Neonates were clustered into two groups, with less than or more than 1500 g birth weight.…”

Section: Ototoxicity Of Gentamicin In Neonatesmentioning

confidence: 99%

Clinical pharmacology of gentamicin in neonates: regimen, toxicology and pharmacokinetics

Pacifici¹

2015

Medical Express

View full text Add to dashboard Cite

Gentamicin is an aminoglycoside antibiotic. It kills bacteria by inhibiting protein synthesis and to some extent by lysing the cell envelope. Gentamicin is frequently the first choice drug because of its reliability, but also because of the long experience with its use. In combination with β-lactam antibiotics it is recommended for the treatment of sepsis or pneumonia and is active against P. aeruginosa, Enterobacter, Klebsiella and Serratia. However, gentamicin is ototoxic and nephrotoxic. The human mitochondrial genetic variant m.1555A > G has been reported to be an important cause of non-syndromic hereditary hearing dysfunction and may cause permanent hearing loss. Even short courses of gentamicin therapy in healty newborn infants can lead to abnormalities of auditory function. It is active against very resistant bacteria at peak concentrations (> 10 mg/l) that are high enough to be potentially toxic. For safe therapeutic efficacy, peak plasma concentrations of gentamicin should range from 4 to 10 mg/l; but trough concentrations, immediately before a new drug administration, must be lower that 2 mg/L to avoid toxic effects. Pharmacokinetic parameters vary considerably in infants. Half-life ranges from 5.4 to 10.0 hours, clearance 0.50 to 1.71 ml/h/kg and distribution volume from 0.4 to 0.7 l/kg. Preterm infants have a longer half-life than full-term infants. Thus, it is mandatory to monitor gentamicin serum concentrations whenever infants are treated for 48 hours or more.

show abstract

Otoacoustic Emission Screen Results in Critically Ill Neonates Who Received Gentamicin in the First Week of Life

Abstract: Neonates weighing more than 1500 g at birth and whose gentamicin C(max) exceeded 10 μg/ml were at an increased risk for OAE screen failure. Monitoring and maintaining gentamicin C(max) at or below 10 μg/ml may minimize hearing impairment; however, further studies are necessary.

Cited by 19 publications

References 34 publications

Gentamicin extended interval regimen and ototoxicity in neonates

Gentamicin extended interval regimen and ototoxicity in neonates

Critical Analysis of a Series of Early Inguinal Ureterostomies: Are They Useful and How Well Are They Tolerated?

Clinical pharmacology of gentamicin in neonates: regimen, toxicology and pharmacokinetics

Contact Info

Product

Resources

About